Proper costimulation of tumor-reactive T lymphocytes may provide a key to unlock their antitumor activity.
Reilly
R Todd
RT
Department of Oncology, The Johns Hopkins School of Medicine; Baltimore, Maryland USA. reilly@jhmi.edu
D053330:4-1BB Ligand; D000818:Animals; D001859:Bone Neoplasms / Q000276:immunology* / Q000517:prevention & control; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D008213:Lymphocyte Activation; D051379:Mice; D012512:Sarcoma, Ewing / Q000276:immunology* / Q000517:prevention & control; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D053330:4-1BB Ligand; C505974:TNFSF9 protein, human; C505975:Tnfsf9 protein, mouse; D014409:Tumor Necrosis Factor-alpha